Sign In
Buy RDHL
$1.00
-0.0100 (-0.99%)
At Close: Jun 03, 2026
RedHill Biopharma Ltd Announces New Movantik Analyses at PAINWeek
06:02am, Tuesday, 07'th Sep 2021
RedHill Biopharma Presents Three New Analyses of Movantik Data at PAINWeek 2021 Two new analyses of Movantik® (naloxegol) data evaluated the safety and efficacy of Movantik in a subgroup of patients
RedHill Biopharma Presents Three New Analyses of Movantik Data at PAINWeek 2021
06:00am, Tuesday, 07'th Sep 2021
TEL AVIV, Israel and RALEIGH, N.C., Sept. 7, 2021 /PRNewswire/ -- RedHill Biopharma Ltd.
RedHill Biopharma to Present at H.C. Wainwright Annual Global Investment and Cantor Global Healthcare Conferences
10:00am, Thursday, 02'nd Sep 2021
TEL AVIV, Israel and RALEIGH, NC, Sept. 2, 2021 /PRNewswire/ -- RedHill Biopharma Ltd.
Why RedHill Biopharma Stock Jumped on Tuesday
04:11pm, Tuesday, 31'st Aug 2021
An analyst on Wall Street thinks the company's commercial and development pipeline has been underestimated.
Cantor Sees 'Compelling Investment Opportunity' In This Biopharma
03:34pm, Tuesday, 31'st Aug 2021
Cantor Fitzgerald has initiated coverage of RedHill Biopharma Ltd (NASDAQ:RDHL) with an Overweight rating and a $22 price target, an upside of approximately 115%. Redhill is focused on the development
RedHill Biopharma Ltd. (RDHL) CEO Dror Ben-Asher on Q2 2021 Results - Earnings Call Transcript
01:07pm, Thursday, 26'th Aug 2021
RedHill Biopharma Ltd. (RDHL) CEO Dror Ben-Asher on Q2 2021 Results - Earnings Call Transcript
RedHill Biopharma reports second quarter 2021 results, showing record quarterly revenues
11:35am, Thursday, 26'th Aug 2021
RedHill Biopharma Ltd. has reported financial results for the second quarter of 2021, showing record quarterly revenues achieved and significant growth for its Talicia and Movantik drugs.
RedHill Biopharma's Oral COVID-19 Candidate Shows Preclinical Action Against Delta Variant
08:44am, Thursday, 26'th Aug 2021
RedHill Biopharma Ltd (NASDAQ: RDHL) has announced preliminary results of a new preclinical study for its COVID-19 treatment candidate, opaganib. Related: RedHill's Novel Late-Stage Pills Hold P
RedHill Biopharma demonstrates strong inhibition by opaganib of the coronavirus (COVID-19) Delta variant
08:13am, Thursday, 26'th Aug 2021
RedHill Biopharma Ltd. has announced results of a new preclinical study demonstrating strong inhibition by its investigational oral pill opaganib (ABC294640) of the coronavirus (COVID-19) Delta varia
RedHill Reports Second Quarter 2021 Results
07:30am, Thursday, 26'th Aug 2021
Achieved record quarterly revenues of $21.5 million for Q2/2021, 4.5% increase from Q1/2021 despite challenging market conditions; Cash balance[1] of approximately $71.5 million as of June 30, 2021 Re
RedHill Biopharma Reports Second Quarter 2021 Financial Results and Operational Highlights
07:00am, Thursday, 26'th Aug 2021
TEL AVIV, Israel and RALEIGH, N.C., Aug. 26, 2021 /PRNewswire/ -- RedHill Biopharma Ltd.
RedHill Biopharma Ltd Announces RedHill's Opaganib Strong Delta Variant Inhibition
06:30am, Thursday, 26'th Aug 2021
RedHill Biopharma's Opaganib Demonstrates Strong Inhibition of COVID-19 Delta Variant Opaganib demonstrated strong inhibition of COVID-19 Delta variant in a human bronchial epithelial cells model, add
RedHill Biopharma's Opaganib Demonstrates Strong Inhibition of COVID-19 Delta Variant
06:00am, Thursday, 26'th Aug 2021
TEL AVIV, Israel and RALEIGH, N.C., Aug. 26, 2021 /PRNewswire/ -- RedHill Biopharma Ltd.
A Preview Of Redhill Biopharma's Earnings
10:18am, Wednesday, 25'th Aug 2021
Redhill Biopharma (NASDAQ:RDHL) will be releasing its next round of earnings this Thursday, August 26. For all of the relevant information, here is your guide for Thursday's Q2 earnings announcement.
RedHill Biopharma says USPTO has issued it with two new patents for opaganib for Ebola Virus and RHB-104 for Crohn's
02:04pm, Monday, 23'rd Aug 2021
RedHill Biopharma Ltd. has announced that the US Patent and Trademark Office (USPTO) has issued the company with two new patents for its drugs, opaganib and RHB-104.
